UNRESECTABLE MELANOMA

This study tests whether adding a personalized cell therapy (lifileucel, made from a patient's own tumor-fighting immune cells) to the standard immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. A…

This study tests a new drug (IOV-3001) that boosts the immune system, given together with a personalized cell therapy (lifileucel) in people with advanced melanoma that has stopped responding to standard treatments. About 42 adults with unresectable or metastatic melanoma will ta…

This study tests a new oral drug, LNS8801, alone or combined with the immunotherapy pembrolizumab, in people with advanced melanoma that has stopped responding to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plu…

This study tests whether eating a diet rich in prebiotic foods can improve how well first-line immunotherapy works in people with advanced melanoma that cannot be removed by surgery. About 75 adults will follow this special diet while starting standard immunotherapy. The goal is …

This study tests two drugs—cabozantinib and nivolumab—in people with advanced melanoma or head and neck cancer that has stopped responding to other treatments. The goal is to see if the combination can shrink or stabilize the cancer, and whether certain tumor biomarkers can predi…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with two anti-rejection medications (sirolimus and prednisone) can control advanced skin cancer in kidney transplant recipients without losing the transplanted kidney. About 16 adults with skin …

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This study tests whether adding the arthritis drug sarilumab to a three-drug immunotherapy cocktail can make treatment safer and more effective for people with advanced (stage III or IV) melanoma that cannot be removed by surgery. About 105 participants will receive the combinati…

This program offers a special cell therapy called AMTAGVI to people with advanced melanoma that cannot be removed by surgery or has spread. The treatment is made from the patient's own immune cells and is normally only given when it meets strict quality standards. Here, patients …

This study looks at whether combining PET/CT scans with a special blood test (ctDNA) can help doctors predict which patients with advanced melanoma will respond to immunotherapy and who might have side effects. About 24 adults with stage III or IV melanoma will be followed for ab…